Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence
FGFR2 mutations may play a role in tumor recurrence in a subset of low-risk endometrial cancers, underscoring the importance of molecular profiling in identifying patients at risk. FGFR2 represents a potential therapeutic target, warranting further validation in larger cohorts to establish its clinical utility.
Authors
- Tuukka Mettälä
- Sakari Hietanen (ORCID: https://orcid.org/0000-0003-4734-4743)
- Titta Joutsiniemi (ORCID: https://orcid.org/0000-0003-2169-9933)
- Jutta Huvila
Institutions
- Turku University Hospital (FI)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.ygyno.2025.03.038
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.11